SLC1A5 and head and neck squamous cell carcinoma: As inhibiting SLC1A5 expression would reduce the survival and sensitize HNSCC cells to cisplatin treatment, SLC1A5 gene-silencing strategy or a chemical inhibitor may facilitate HNSCC/OSCC therapy [22].